Yüklüyor…
HCV: The Journey from Discovery to a Cure Volume II /
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus...
Müşterek Yazar: | |
---|---|
Diğer Yazarlar: | |
Materyal Türü: | e-Kitap |
Dil: | İngilizce |
Baskı/Yayın Bilgisi: |
Cham :
Springer International Publishing :
2019.
Imprint: Springer, |
Edisyon: | 1st ed. 2019. |
Seri Bilgileri: | Topics in Medicinal Chemistry,
32 |
Konular: | |
Online Erişim: | Full-text access |
İçindekiler:
- NS5A as a target for HCV Drug Discovery
- The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex
- The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®
- The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa® and Vosevi®
- Discovery of Elbasvir
- HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
- Evolution of HCV NS4B Inhibitors
- The Evolution of Clinical Trials for Hepatitis C
- The Clinical Development of Ledipasvir/Sofosbuvir (LDV/SOF, Harvoni®)
- The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa®)
- The Clinical Development of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX, Vosevi®)
- Clinical Development of Viekira Pak to Mavyret
- Development of ZEPATIER®
- Real world effectiveness of DAA therapies
- The Benefit of Direct-Acting Antiviral HCV Cure Therapies
- Cure and Control: What Will It Take to Eliminate HCV?
- Perspectives on HCV Cure.